Skip to main content
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALDX ISIN · US01438T1060 LEI · 529900HGKY864E4Y9014 US Manufacturing
Filings indexed 621 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US ALDX

About Aldeyra Therapeutics, Inc.

https://www.aldeyra.com/

Aldeyra Therapeutics is a biotechnology company developing medications for immune-mediated diseases. The company's therapeutic approach involves modulating immunological systems rather than inhibiting or activating single protein targets, with the goal of optimizing multiple pathways while minimizing toxicity. Its portfolio of product candidates targets inflammatory cells associated with both ocular and systemic ailments. Aldeyra has investigational therapies in late-stage clinical development for conditions such as dry eye disease and allergic conjunctivitis, aiming to address medical needs not adequately met by existing treatments.

Recent filings

Filing Released Lang Actions
10-Q - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
Annual Report
2026-04-27 English
8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the payoff and termination of a credit facility (loan agreement) and the resulting termination of the facility. There are no financial statements or detailed financial analysis, only an update on financing activity. The document length is 3515 characters, which is relatively short and focused on a specific financing event. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories. Therefore, the appropriate classification is CAP with high confidence.
2026-04-01 English
SCHEDULE 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
Director's Dealing
2026-03-20 English
4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)
Director's Dealing
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.